Healthcare / BiotechnologyLSE
$0.70
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-550078.00 · quality 60.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-60.0%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.9%
FCF CAGR
—
FCF margin
-70.2%
FCF / Net income
1.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $784005.0 · net income $-415254.0 · FCF $-550078.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $784005.00 | $784005.00 | $543250.00 | $597354.00 | $830266.00 |
| Net Income | $-415254.00 | $-415254.00 | $-609352.00 | $-477257.00 | $-253138.00 |
| EBITDA | $-448206.00 | $-448206.00 | $-659771.00 | $-561570.00 | $-347979.00 |
| EPS | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Operating Margin | -58.4% | -58.4% | -123.5% | -96.0% | -43.3% |
| Net Margin | -53.0% | -53.0% | -112.2% | -79.9% | -30.5% |
| Balance Sheet | |||||
| Current Ratio | 3.30 | 3.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-550078.00 | $-550078.00 | $-565443.00 | $-273223.00 | $-358763.00 |
| Returns | |||||
| ROE | -60.0% | -60.0% | -215.7% | -89.8% | -26.0% |
| Valuation | |||||
| P/B | 240.86 | 240.86 | 311.44 | 178.65 | 289.68 |
| Growth & Yield | |||||
| Revenue Growth | 44.3% | 44.3% | -9.1% | -28.1% | — |
| EPS Growth | 62.2% | 62.2% | 8.2% | -88.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+52.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.00
Residual
+52.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.